Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer

NCT05198804 is registered in ClinicalTrials.gov with K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc as lead sponsor.

NCT NCT05198804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05198804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase
Phase 1/2
Overall status
Completed
Start date
January 27, 2022
Completion date
January 19, 2026
Enrollment
117 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, platinum-resistant ovarian cancer, primary peritoneal carcinoma